FIG 5.

CMVs derived from S. aureus NRS77^phage stimulated with MMC or FLU protect a clinical S. aureus strain from DAP treatment. Log-phase cultures of the clinical S. aureus isolate CI1449 were treated with 10 times the MIC of DAP in the presence or absence of two different concentrations of CMVs (62.5 or 31.25 μg protein/ml) derived from S. aureus NRS77^phage stimulated with either MMC (100 ng/ml) (A and B) or FLU (10× MIC) (C and D). The viability of the S. aureus clinical isolate CI1449 was followed over 24 h. Strain CI1449 is resistant to infection by phages produced by strain NRS77^phage upon treatment with MMC. High inoculum, 5 × 10⁷ CFU/ml; low inoculum, 10⁵ CFU/ml. Missing data points indicate no detectable live bacteria; the lower limit of detection for this assay is 10³ CFU/ml. The graphs show data from at least three independent experiments.